Ziihera Win + Cash Flow: Why Jazz Looks Poised for a Multiple Re-Rate
Jazz Pharmaceuticals pairs a string of commercial assets and a positive Phase 3 oncology readout with strong free cash flow and reasonable leverage. That combination supports a re-rating thesis: market is paying a mid-teens multiple today; successful commercialization and additional registry/label wins could push Jazz toward premium biotech/oncolog…